Research Analysts’ Recent Ratings Updates for Trevena (TRVN)

A number of research firms have changed their ratings and price targets for Trevena (NASDAQ: TRVN):

• 5/15/2022 – Trevena is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 5/12/2022 – Trevena had its price target lowered by analysts at HC Wainwright from $5.00 to $3.50.
• 5/7/2022 – Trevena is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 4/29/2022 – Trevena is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 4/21/2022 – Trevena is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 4/13/2022 – Trevena is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 4/4/2022 – Trevena was upgraded by analysts at StockNews.com to a “sell” rating.

Shares of NASDAQ:TRVN opened at $0.30 on Tuesday. Trevena, Inc. has a 1 year low of $0.18 and a 1 year high of $2.20. The business has a fifty day simple moving average of $0.39 and a 200 day simple moving average of $0.55. The firm has a market cap of $50.12 million, a price-to-earnings ratio of -0.87 and a beta of 2.44.

Trevena (NASDAQ:TRVN – Get Rating) last posted its quarterly earnings data on Wednesday, May 11th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). Trevena had a negative return on equity of 74.90% and a negative net margin of 7,771.74%. During the same period in the prior year, the business earned ($0.06) earnings per share. On average, sell-side analysts anticipate that Trevena, Inc. will post -0.34 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Arbitrage SA boosted its holdings in shares of Trevena by 454.1% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 34,896 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 28,598 shares in the last quarter. Bank of America Corp DE raised its position in shares of Trevena by 48.1% during the 2nd quarter. Bank of America Corp DE now owns 34,607 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 11,243 shares during the last quarter. Two Sigma Advisers LP bought a new stake in shares of Trevena during the 3rd quarter valued at $60,000. Invesco Ltd. acquired a new position in shares of Trevena in the 2nd quarter valued at $73,000. Finally, Barclays PLC acquired a new position in shares of Trevena in the 3rd quarter valued at $83,000. 21.20% of the stock is currently owned by institutional investors.

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.

Featured Stories